Things Are Starting To Break
In late September I wrote a blog titled “Something Is Going To Break”. The premise was that if the Fed didn’t start to ease up...
Category : Uncategorized
Activision Blizzard upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Andrew Marok upgraded Activision Blizzard (ATVI) to Outperform from Market Perform with a $95 price target. Following last year’s announcement that Microsoft...
Russia’s Oil Output Set To Fall By 1.5 Million Bpd In December
Russia’s oil production could drop to as low as 9 million barrels per day (bpd) in December when the EU embargo on imports of Russian...
Asia Markets Mixed
Asia-Pacific stocks were mixed as investors digest incoming results of the United States midterm elections and China’s annualized producer prices fell for the first time...
Beyond Meat price target lowered to $11 from $27 at Mizuho
Mizuho analyst John Baumgartner lowered the firm’s price target on Beyond Meat to $11 from $27 and keeps a Neutral rating on the shares post...
EU Leaders Accuse U.S. Natural Gas Producers Of Profiteering
Last month, France’s president Emmanuel Macron accused the United States of a “double standard” because of the difference between the price at which liquefied natural...
Parts iD downgraded to Hold after ‘soft’ Q3 at Canaccord
Canaccord analyst Maria Ripps downgraded Parts iD to Hold from Buy with a price target of $3, down from $4. The company repotted “soft” Q3...
Crude Inventory Build Sends Oil Prices Lower
Crude oil prices moved lower today after the Energy Information Administration reported a crude oil inventory build of 3.9 million barrels for the week to...
Arcturus Therapeutics downgraded to Underperform from Neutral at Baird
Baird analyst Joel Beatty downgraded Arcturus Therapeutics to Underperform from Neutral with an $18 price target. Post the Q3 results, the analyst has decreased conviction...
JPMorgan downgrades Roblox on more modest sales growth outlook
JPMorgan analyst David Karnovsky downgraded Roblox to Neutral from Overweight with a price target of $35, down from $53, post the Q3 results. Though the...